Skip to main content
. Author manuscript; available in PMC: 2022 Apr 7.
Published in final edited form as: J Pharm Sci. 2020 Oct 27;110(4):1693–1700. doi: 10.1016/j.xphs.2020.10.046

Figure 6.

Figure 6.

Lenalidomide daily release profiles from pCD-γ-MP, pCD-γ-MP (ground), and γ-disks (A). Days of continuous non-zero release of LND from each formulation (B). * indicates p < 0.05 by two-way ANOVA with Tukey test post-hoc between the disks and both the pCD-γ-MP and pCD-γ-ground MP groups at 3–96 hours post-incubation (A) and by one-way ANOVA with Bonferonni post-hoc for cumulative days of release between the disks and both the pCD-γ-MP and pCD-γ-ground MP (B). n=3 replicates per condition. Error bars represent the standard error of the mean (A) and standard deviation (B).